Shilpa Medicare - Weak Q3 Performance; Warning Letter Is An Overhang: ICICI Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Shilpa Medicare Ltd. reported Q3 FY21 results below our estimates due to lower formulations revenue on account of remediation activities at manufacturing unit.
Revenue declined 19.3% YoY to Rs 1.9 billion (our estimate Rs 2.7 billion), Ebitda margin dropped 2010 basis points YoY to 11.0% (our estimate 24.8%) on high base and lower revenue and adjusted profit after tax was down 86.1% to Rs 77 million.
Formulations revenue was down 58.2% QoQ to Rs 343 million as there was temporary shutdown of manufacturing.
The company is implementing the remedial measures post warning letter and has engaged a third party consultant for the same.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.